Evidence map›Paper›PMID 41557677›Full record

ArticlePloS one2026

Oxyphenbutazone improves memory and learning impairments in LPS-induced neurotoxicity via modulating TGF-β/NF-κB/IκB-α pathways: In silico and in vivo study.

Khalid Saad Alharbi, Muhammad Afzal, Sattam Khulaif Alenezi, Reem ALQahtani, Tariq G Alsahli, Faisal Imam, Imran Kazmi

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Khalid Saad AlharbiDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Al Qassim 51452, Saudi Arabia.
Muhammad AfzalDepartment of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeddah 21442, Saudi Arabia.ORCID https://orcid.org/0000-0003-2570-3223
Sattam Khulaif AleneziDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Al Qassim 51452, Saudi Arabia.
Reem ALQahtaniDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdul Rahman University, Riyadh, KSA.
Tariq G AlsahliDepartment of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Aljouf, 72341, Saudi Arabia.
Faisal ImamDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11452, P.O. Box 145111, Saudi Arabia.
Imran KazmiDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveNeuroinflammation and oxidative stress play key roles in cognitive decline and memory impairments. This study employed a lipopolysaccharide (LPS)-induced neurotoxicity model and in silico methods, including in silico docking and dynamic simulations, to assess the therapeutic potential of Oxyphenbutazone (OPB). MATERIALS AND

methodsWistar rats were categorized as control, LPS-only section, LPS + OPB receiving low (35 mg/kg) and high (70 mg/kg) doses of OPB, and only OPB (70 mg/kg) doses. Behavioral assessments (Y-maze and Morris water tests) were used to assess cognitive ability. The levels of neuroinflammatory markers [Interleukin-6 (IL-6), IL-1β, and tumor necrosis factor-alpha (TNF-α)] and oxidative stress modulators [Superoxide dismutase (SOD), glutathione (GSH), catalase (CAT), and malondialdehyde (MDA)] were estimated. Additionally, transforming growth factor-beta (TGF-β), nuclear factor-kappa B (NF-κB), and inhibitor of kappa B-alpha (IκB-α) levels were evaluated. In silico analyses, such as molecular docking and dynamic simulations, were used to evaluate the stability of OPB and target molecules.

resultsCognitive performance improved after OPB treatment, and the levels of proinflammatory cytokines, antioxidants, TGF-β, NF-κB, and IκB-α were restored. Additionally, in silico analyses illustrated favorable and stable interactions between OPB and the target molecules NF-κB and IκB-α.

conclusionThese findings suggest the therapeutic potential of OPB in mitigating neurotoxicity and the associated cognitive disabilities.

Indexed as

Learning DisabilitiesMemory DisordersNeurotoxicity SyndromesNF-kappa BNF-KappaB Inhibitor alphaPhenylbutazoneTransforming Growth Factor betaAnimalsComputer SimulationLipopolysaccharidesMaleMaze LearningMemoryMolecular Docking SimulationOxidative StressRatsLipopolysaccharidesNF-kappa BNF-KappaB Inhibitor alphaPhenylbutazoneTransforming Growth Factor beta

Identifiers

PMID41557677
PMCPMC12818642

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.